MDR1 gene expression and drug resistance of AML cells

British Journal of Haematology

Volumn 100, Issue 3, 1998, Pages 534-540

  Nørgaard, Jan Maxwell ^a,b   Bukh, Anne ^a   Langkjer, Sven Tyge ^a   Clausen, Neils ^a   Palshof, Torben ^a   Hokland, Peter ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b Aarhus Amtsygehus ^*  (Denmark)

Author keywords

AML; Competitive RT PCR; MDR1; MTT assay, Drug resistance

Indexed keywords

ACLARUBICIN; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; GLYCOPROTEIN P; MITOXANTRONE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY C 129; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; BLAST TRANSFORMATION; BLOOD SAMPLING; CROSS REACTION; CYTOTOXICITY; DATA ANALYSIS; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; LEUKEMIA CELL; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPECTROPHOTOMETRY;

ACLARUBICIN; ACUTE DISEASE; ANTINEOPLASTIC AGENTS; CYTARABINE; DAUNORUBICIN; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; ETOPOSIDE; GENE EXPRESSION; GENES, MDR; HUMANS; LETHAL DOSE 50; LEUKEMIA, MYELOID; MITOXANTRONE; TUMOR CELLS, CULTURED;

EID: 0031811301     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.1998.00593.x     Document Type: Article

References (28)

1. Campos, L., Guyotat, D., Archimbaud, E., Calmard-Oriol, P., Tsuruo, T., Troncy, J., Treille, D. & Fiere, D. (1992) Clinical significance of multidrug resistance p-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis. Blood, 79, 473-476.
2. Chen, C.J., Clark, D., Ueda, K., Pastan, I., Gottesman, M.M. & Roninson, I.B. (1990) Genomic organization of the human multidrug resistance (MDR1) gene and origin of P-glycoproteins. Journal of Biological Chemistry, 265, 506-514.
3. Coley, H.M., Twentyman, P.R. & Workman, P. (1989) Improved cellular accumulation is characteristic of anthracyclines which retain high activity in multidrug resistant cell lines, alone or in combination with verapamil or cyclosporin. Biochemical Pharmacology, 38, 4467-4475.
4. Coley, H.M., Twentyman, P.R. & Workman, P. (1990) 9-Alkyl, morpholinyl anthracyclines in the circumvention of multidrug resistance. European Journal of Cancer, 26, 665-667.
5. Del Poeta, G., Stasi, R., Aronica, G., Venditti, A., Cox, M.C., Bruno, A., Buccisano, F., Masi, M., Tribalto, M., Amadori, S. & Papa, G. (1996) Clinical relevance of P-glycoprotein expression in de novo acute myeloid leukemia. Blood, 87, 1997-2004.
6. Dong, J., Naito, M., Tatsuta, T., Seimiya, H., Johdo, O. & Tsuruo, T. (1995) Difference between the resistance mechanisms of aclacinomycin- and adriamycin-resistant P388 cell lines. Oncology Research, 7, 245-252.
7. Guerci, A., Merlin, J.L., Missoum, N., Feldmann, L., Marchal, S., Witz, F., Rose, C. & Guerci, O. (1995) Predictive value for treatment outcome in acute myeloid leukemia of cellular daunorubicin accumulation and P-glycoprotein expression simultaneously determined by flow cytometry. Blood, 85, 2147-2153.
8. Hansen, O.P., Pedersen-Bjergaard, J., Ellegaard, J., Brincker, H., Boesen, A.M., Christensen, B.E., Drivsholm, A., Hippe, E., Jans, H., Jensen, K.B., Killmann, S., Jensen, M.K., Karle, H., Laursen, B., Nielsen, J.B., Nissen, N.I. & Thorling, K. (1991) Aclarubicin plus cytosine arabinoside versus daunorubicin plus cytosine arabinoside in previously untreated acute myeloid leukemia: a Danish national phase III trial. Leukemia, 5, 510-516.
9. Jensen, P.B., Jensen, P.S., Demant, E.J., Friche, E., Sorensen, B.S., Sehested, M., Wassermann, K., Vindelov, L., Westergaard, O. & Hansen, H.H. (1991) Antagonistic effect of aclarubicin on daunorubicin-induced cytotoxicity in human small cell lung cancer cells: relationship to DNA integrity and topoisomerase II. Cancer Research, 51, 5093-5099.
10. Jensen, P.B., Sorensen, B.S., Sehested, M., Demant, E.J., Kjeldsen, E., Friche, E. & Hansen, H.H. (1993) Different modes of anthracycline interaction with topoisomerase II: separate structures critical for DNA-cleavage, and for overcoming topoisomerase II-related drug resistance. Biochemical Pharmacology, 45, 2025-2035.
11. Jensen, P.B., Vindelov, L., Roed, H., Demant, E.J., Sehested, M., Skovsgaard, T. & Hansen, H.H. (1989) In vitro evaluation of the potential of aclarubicin in the treatment of small cell carcinoma of the lung (SCCL). British Journal of Cancer, 60, 838-844.
12. Kamps, M.P., Murre, C., Sun, X. & Baltimore, D. (1990) A new homeobox gene contributes the DNA binding domain of the t(1:19) translocation protein in pre-B ALL. Cell, 60, 547-555.
13. Kartner, N., Evernden-Porelle, D., Bradley, G. & Ling, V. (1985) Detection of P-glycoprotein in multidrug-resistant cell lines by monoclonal antibodies. Nature, 316, 820-823.
14. Klumper, E., Pieters, R., den Boer, M.L., Huismans, D.R., Loonen, A.H. & Veerman, A.J. (1995) In vitro anthracycline cross-resistance pattern in childhood acute lymphoblastic leukaemia. British Journal of Cancer, 71, 1188-1193.
15. Krajewski, S., Blomqvist, C., Franssila, K., Krajewska, M., Wasenius, V.M., Niskanen, E., Nordling, S. & Reed, J.C. (1995) Reduced expression of proapoptotic gene BAX is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma. Cancer Research, 55, 4471-4478.
16. List, A.F., Spier, C., Greer, J., Wolff, S., Hutter, J., Dorr, R., Salmon, S., Futscher, B., Baier, M. & Dalton, W. (1993) Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia. Journal of Clinical Oncology, 11, 1652-1660.
17. Marie, J.P., Zittoun, R. & Sikic, B.I. (1991) Multidrug resistance (mdr1) gene expression in adult acute leukemias: correlations with treatment outcome and in vitro drug sensitivity. Blood, 78, 586-592.
18. Nørgaard, J.M., Langkjer, S.T., Palshof, T., Clausen, N., Pedersen, B. & Hokland, P. (1996) Relation of blast cell survival and proliferation to chemotherapy resistance in AML. British Journal of Haematology, 95, 888-897.
19. Perego, P., Giarola, M., Righetti, S.C., Supino, R., Caserini, C., Delia, D., Pierotti, M.A., Miyashita, T., Reed, J.C. & Zunino, F. (1996) Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems. Cancer Research, 56, 556-562.
20. Pirker, R., Wallner, J., Geissler, K., Linkesch, W., Haas, O.A., Bettelheim, P., Hopfner, M., Scherrer, R., Valent, P., Havelec, L., Ludwig, H. & Lechner, K. (1991) MDR1 gene expression and treatment outcome in acute myeloid leukemia. Journal of the National Cancer Institute, 83, 708-712.
21. Riva, C.M. & Rustum, Y.M. (1985) 1-beta-D-arabinofuranosylcytosine metabolism and incorporation into DNA as determinants of in vivo murine tumor cell response. Cancer Research, 45, 6244-6249.
22. Salmon, S.E., Dalton, W.S., Grogan, T.M., Plezia, P., Lehnert, M., Roe, D.J. & Miller, T.P. (1991) Multidrug-resistant myeloma: laboratory and clinical effects of verapamil as a chemosensitizer. Blood, 78, 44-50.
23. Scheffer, G.L., Wijngaard, P.L., Flens, M.J., Izquierdo, M.A., Slovak, M.L., Pinedo, H.M., Meijer, C.J., Clevers, H.C. & Scheper, R.J. (1995) The drug resistance-related protein LRP is the human major vault protein. Nature Medicine, 1, 578-582.
24. Schneider, E., Cowan, K.H., Bader, H., Toomey, S., Schwartz, G.N., Karp, J.E., Burke, P.J. & Kaufmann, S.H. (1995) Increased expression of the multidrug resistance-associated protein gene in relapsed acute leukemia. Blood, 85, 186-193.
25. Sehested, M., Friche, E., Jensen, P.B. & Demant, E.J. (1992) Relationship of VP-16 to the classical multidrug resistance phenotype. Cancer Research, 52, 2874-2879.
26. Sonneveld, P., Durie, B.G., Lokhorst, H.M., Marie, J.P., Solbu, G., Suciu, S., Zittoun, R., Lowenberg, B. & Nooter, K. (1992) Modulation of multidrug-resistant multiple myeloma by cyclosporin. The Leukaemia Group of the EORTC and the HOVON. Lancet, 340, 255-259.
27. Twentyman, P.R. (1995) Modifiers of multidrug resistance. British Journal of Haematology, 90, 735-737.
28. Watada, H., Kajimoto, Y., Umayahara, Y., Matsuoka, T., Morishima, T., Yamasaki, Y. Kawamori, R. & Kamada, T. (1995) Ubiquitous, but variable, expression of two alternatively spliced mRNAs encoding mouse homologues of transcription factors E47 and E12. Gene, 153, 255-259.